Suppr超能文献

低细胞密度培养可延缓人骨髓间充质干细胞在长期培养中的细胞衰老。

Culturing at Low Cell Density Delays Cellular Senescence of Human Bone Marrow-Derived Mesenchymal Stem Cells in Long-Term Cultures.

作者信息

Kim Si-Na, Choi Byeol, Lee Chan-Ju, Moon Jeong Hyun, Kim Min Kyoung, Chung Eunkyung, Song Sun Uk

机构信息

SCM Lifesciences Co. Ltd., Incheon, Korea.

Department of Biomedical Sciences, Inha University College of Medicine, Incheon, Korea.

出版信息

Int J Stem Cells. 2021 Feb 28;14(1):103-111. doi: 10.15283/ijsc20078.

Abstract

BACKGROUND AND OBJECTIVES

Mesenchymal stem cells (MSCs) have immense therapeutic potential for treating intractable and immune diseases. They also have applications in regenerative medicine in which distinct treatments do not exist. Thus, MSCs are gaining attention as important raw materials in the field of cell therapy. Importantly, the number of MSCs in the bone marrow is limited and they are present only in small quantities. Therefore, mass production of MSCs through long-term culture is necessary to use them in cell therapy. However, MSCs undergo cellular senescence through repeated passages during mass production. In this study, we explored methods to prolong the limited lifetime of MSCs by culturing them with different seeding densities.

METHODS AND RESULTS

We observed that in long-term cultures, low-density (LD, 50 cells/cm) MSCs showed higher population doubling level, leading to greater fold increase, than high-density (HD, 4,000 cells/cm) MSCs. LD-MSCs suppressed the expression of aging-related genes. We also showed that reactive oxygen species (ROS) were decreased in LD-MSCs compared to that in HD-MSCs. Further, proliferation potential increased when ROS were inhibited in HD-MSCs.

CONCLUSIONS

The results in this study suggest that MSC senescence can be delayed and that life span can be extended by controlling cell density . These results can be used as important data for the mass production of stem cell therapeutic products.

摘要

背景与目的

间充质干细胞(MSCs)在治疗难治性疾病和免疫性疾病方面具有巨大的治疗潜力。它们在再生医学中也有应用,而目前尚无明确的治疗方法。因此,MSCs作为细胞治疗领域的重要原材料正受到关注。重要的是,骨髓中MSCs的数量有限且仅少量存在。因此,为了在细胞治疗中使用MSCs,有必要通过长期培养进行大规模生产。然而,在大规模生产过程中,MSCs会因反复传代而发生细胞衰老。在本研究中,我们探索了通过不同接种密度培养MSCs来延长其有限寿命的方法。

方法与结果

我们观察到,在长期培养中,低密度(LD,50个细胞/cm²)的MSCs比高密度(HD,4000个细胞/cm²)的MSCs表现出更高的群体倍增水平,导致更大的倍增倍数。LD-MSCs抑制了衰老相关基因的表达。我们还表明,与HD-MSCs相比,LD-MSCs中的活性氧(ROS)减少。此外,当HD-MSCs中的ROS被抑制时,其增殖潜力增加。

结论

本研究结果表明,通过控制细胞密度可以延缓MSCs衰老并延长其寿命。这些结果可作为干细胞治疗产品大规模生产的重要数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d131/7904528/f6ee4db85866/ijsc-14-1-103-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验